These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Rodriguez AL; Grier MD; Jones CK; Herman EJ; Kane AS; Smith RL; Williams R; Zhou Y; Marlo JE; Days EL; Blatt TN; Jadhav S; Menon UN; Vinson PN; Rook JM; Stauffer SR; Niswender CM; Lindsley CW; Weaver CD; Conn PJ Mol Pharmacol; 2010 Dec; 78(6):1105-23. PubMed ID: 20923853 [TBL] [Abstract][Full Text] [Related]
13. A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Rodriguez AL; Nong Y; Sekaran NK; Alagille D; Tamagnan GD; Conn PJ Mol Pharmacol; 2005 Dec; 68(6):1793-802. PubMed ID: 16155210 [TBL] [Abstract][Full Text] [Related]
14. Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5). Stauffer SR ACS Chem Neurosci; 2011 Aug; 2(8):450-70. PubMed ID: 22860171 [TBL] [Abstract][Full Text] [Related]
15. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. Liu F; Grauer S; Kelley C; Navarra R; Graf R; Zhang G; Atkinson PJ; Popiolek M; Wantuch C; Khawaja X; Smith D; Olsen M; Kouranova E; Lai M; Pruthi F; Pulicicchio C; Day M; Gilbert A; Pausch MH; Brandon NJ; Beyer CE; Comery TA; Logue S; Rosenzweig-Lipson S; Marquis KL J Pharmacol Exp Ther; 2008 Dec; 327(3):827-39. PubMed ID: 18753411 [TBL] [Abstract][Full Text] [Related]
16. Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity. Rook JM; Noetzel MJ; Pouliot WA; Bridges TM; Vinson PN; Cho HP; Zhou Y; Gogliotti RD; Manka JT; Gregory KJ; Stauffer SR; Dudek FE; Xiang Z; Niswender CM; Daniels JS; Jones CK; Lindsley CW; Conn PJ Biol Psychiatry; 2013 Mar; 73(6):501-9. PubMed ID: 23140665 [TBL] [Abstract][Full Text] [Related]
17. Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254). Turlington M; Noetzel MJ; Chun A; Zhou Y; Gogliotti RD; Nguyen ED; Gregory KJ; Vinson PN; Rook JM; Gogi KK; Xiang Z; Bridges TM; Daniels JS; Jones C; Niswender CM; Meiler J; Conn PJ; Lindsley CW; Stauffer SR J Med Chem; 2013 Oct; 56(20):7976-96. PubMed ID: 24050755 [TBL] [Abstract][Full Text] [Related]
18. Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. Zhang Y; Rodriguez AL; Conn PJ J Pharmacol Exp Ther; 2005 Dec; 315(3):1212-9. PubMed ID: 16135701 [TBL] [Abstract][Full Text] [Related]
19. Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA. Zhao Z; Wisnoski DD; O'Brien JA; Lemaire W; Williams DL; Jacobson MA; Wittman M; Ha SN; Schaffhauser H; Sur C; Pettibone DJ; Duggan ME; Conn PJ; Hartman GD; Lindsley CW Bioorg Med Chem Lett; 2007 Mar; 17(5):1386-91. PubMed ID: 17210250 [TBL] [Abstract][Full Text] [Related]